

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/603,841
		Filing Date	June 25, 2003
Date Submitted: JUL 05 2005		First Named Inventor	Richard M. Fleming
		Group Art Unit	1661
(use as many sheets as necessary)		Examiner Name	
		Attorney Docket Number	037811/0103
Sheet	1	of	1

PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code <sup>2</sup> (if known)				
		5,895,640		Khalkhali	04-20-1999	424/1.65	
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>
NE		"Breast Enhanced Scintigraphy Testing" or "B.E.S.T." A description of the B.E.S.T. imaging method may be found in Fleming RM, Dooley WC, Boyd LB, Kubovy C, "Breast Enhanced Scintigraphy Testing (B.E.S.T.) - Increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging," 48th Annual Scientific Session of the Society of Nuclear Medicine, Toronto, Ontario, Canada, 26 June 2001.					
NE		"Comparing a High Dose Dipyridamole SPECT Imaging protocol with Dobutamine and Exercise Stress Testing Protocols: Part III: Using Dobutamine to Determine Lung-to-Heart Ratios, Left Ventricular Dysfunction and a potential Viability Marker," Intern J of Angiol 1999, 8:22-26.					
NE		Fleming RM, "Chapter 29 of Atherosclerosis: Understanding the Relationship Between Coronary Artery Disease and Stenosis Flow Reserve," Textbook of Angiology, John C. Chang Editor, Springer-Verlag New York, NY 1999, pp. 381-387.					
NE		Fleming RM, "Chapter 31. Nuclear Cardiology: Its Role in the Detection and Management of Coronary Artery Disease," Textbook of Angiology, John C. Chang Editor, Springer-Verlag New York, NY 1999, pp. 397-406.					
NE		Fleming RM, Boyd L, Forster M, "Angina is Caused by Regional Blood Flow Differences - Proof of a Physiologic (Not Anatomic) Narrowing," Joint Session of the European Society-American College of Cardiology, ACC 49th Annual Scientific Sessions, March 12, 2000 (www.prou.com)					
NE		Fleming RM, "Coronary artery disease is more than just coronary lumen disease," Am J Card 2001, 88:599-600.					
NE		Glodman, Erik; "Novel Imaging Technique Reveals Breast Benefits of Soy Supplementation", Holistic Primary Care, April 15, 2002.					
NE		"Revival Soy and Breast Inflammation", Holistic Primary Care, April 15, 2002.					
NE		Fleming, RM et al. "Comparing aHigh-Dose Dipyridamole SPECT Imaging Protocol With Doputamine And Exercise Stress Testing Protocols," Angiology, the Journal of Vascular Diseases, Vol. 46, No. 7, July 1995, pp 547-556.					

Examiner Signature	<i>N</i>	Date Considered	6/13/06
--------------------	----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.